Chardan Capital Keeps a Buy Rating on Crispr Therapeutics AG (CRSP)

By Jason Carr

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Crispr Therapeutics AG (CRSPResearch Report) today and set a price target of $72.50. The company’s shares closed last Monday at $37.96.

According to TipRanks.com, Livshits is ranked 0 out of 5 stars with an average return of -14.1% and a 20.7% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Logicbio Therapeutics Inc, and Intellia Therapeutics.

Crispr Therapeutics AG has an analyst consensus of Strong Buy, with a price target consensus of $69.56.

See today’s analyst top recommended stocks >>

The company has a one-year high of $53.90 and a one-year low of $22.22. Currently, Crispr Therapeutics AG has an average volume of 489.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, and Shaun Patrick Foy in 2014 and is headquartered in Zug, Switzerland.